MKI67 and breast carcinoma: Our study population of 80 patients showed a complete pathological response of 60% in patients having a Ki-67 value of more than 35% with a significant p value of 0.00018 even though 50% of our study population had T3 and T4 tumors as compared to the Gepartrio trial having a majority of T2 tumors showing that Ki-67 is an independent predictor of response to chemotherapy in breast cancer patients.